Peptide library / Heart & blood / Terlipressin
Terlipressin
A vasopressin prodrug used for kidney failure in advanced liver disease.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Hepatorenal syndrome with rapid kidney declineFDA approved
How it is thought to work
Terlipressin tightens blood vessels in the gut and improves blood flow to the kidneys in hepatorenal syndrome.
What the evidence shows
The CONFIRM trial showed more patients had reversal of hepatorenal syndrome than with placebo.
Safety and unknowns
A boxed warning concerns serious or fatal respiratory failure. Reduced blood flow to fingers and gut can occur.
Regulatory status
FDA-approved as Terlivaz in 2022.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Heart & blood
Ularitide
In clinical trialsA kidney-derived natriuretic peptide tested in acute heart failure and found not to help.
Angiotensin 1-7
In clinical trialsA seven amino acid fragment that opposes angiotensin II, studied in several conditions.
Serelaxin
In clinical trialsRecombinant human relaxin-2, a pregnancy hormone tested in acute heart failure.
General information, not medical advice. Do not buy or inject unregulated peptides.